We’re excited to put into the spotlight our strategic collaboration with the VIB-KU Leuven Center for Cancer Biology (VIB-CCB) – a partnership that’s pushing the boundaries of what’s possible in precision oncology.

Over the past months, we brought together our complementary strengths in single-cell analysis, TCR repertoire profiling, and next-generation antigen discovery.

By merging VIB’s world-class single-cell cancer atlas and TCR sequencing expertise with myNEO’s ImmunoEngine platform, we’re uncovering deeper insights into camyotopes in terms of expression patterns, clonality, and tumor specificity, while ongoing TCR cross-matching studies are helping determine whether these targets elicit natural immune responses in patients. Early results show strong tumor specificity, compelling immunogenicity signals, and exciting opportunities for future clinical translation. We also partnered on evaluating splicing-derived neoantigens, where myNEO’s ImmunoEngine tool suite (neoMS & neoIM) supported VIB’s recent publication on single-cell splicing patterns linked to immunotherapy response.

This collaboration is a powerful example of how combining deep biology with cutting-edge computational immunology can unlock the next wave of transformative cancer targets. We are excited for what else our collaboration will bring as we continue our efforts in the upcoming year to discover and validate high-impact cancer targets for innovative immunotherapeutics.